KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT) (www.provectusbio.com), a clinical-stage oncology and dermatology biopharmaceutical company (“Provectus” or the "Company”), today announced its financial results for the first quarter 2016 ended March 31, 2016.
